COST-EFFECTIVENESS ANALYSIS OF PANITUMUMAB PLUS MFOLFOX6 VERSUS BEVACIZUMAB PLUS MFOLFOX6 FOR FIRST-LINE TREATMENT OF PATIENTS WITH WILD-TYPE RAS METASTATIC COLORECTAL CANCER

被引：0
|
作者：
Graham, C. N. [1 ]
Hechmati, G. [2 ]
Hjelmgren, J. [2 ]
De Liege, F. [3 ]
Lanier, J. [3 ]
Knoof, A. [3 ]
Knox, H. [1 ]
Barber, B. [4 ]
de Pouvourville, G. [5 ]
机构：
[1] RTI Hlth Solut, Res Triangle Pk, NC USA
[2] Amgen Europe GmbH, Zug, Switzerland
[3] Amgen France SAS, Neuilly Sur Seine, France
[4] Amgen Inc, Thousand Oaks, CA 91320 USA
[5] ESSEC Business Sch, Cergy Pontoise, France
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.2264
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN106
引用
收藏
页码：A632 / A632
页数：1
相关论文
共 50 条
  • [31] BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer
    Benson, Al B., III
    Kiss, Igor
    Bridgewater, John
    Eskens, Ferry A. L. M.
    Sasse, Carolyn
    Vossen, Sandra
    Chen, Jihong
    Van Sant, Chip
    Ball, Howard A.
    Keating, Anne
    Krivoshik, Andrew
    CLINICAL CANCER RESEARCH, 2016, 22 (20) : 5058 - 5067
  • [32] SIRFLOX: Differences in site of first progression between mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6 ± bev plus selective internal radiation therapy (SIRT) in first-line patients (pts) with metastatic colorectal cancer (mCRC).
    Gibbs, Peter
    Heinemann, Volker
    Sharma, Navesh K.
    Findlay, Michael P. N.
    Ricke, Jens
    Peeters, Marc
    Perez, David
    Robinson, Bridget Anne
    Strickland, Andrew
    Ferguson, Tom
    Rodriguez, Javier
    Kroening, Hendrik
    Wolf, Ido
    Ganju, Vinod
    Walpole, Euan Thomas
    Boucher, Eveline
    Tichler, Thomas E.
    Gebski, Val
    Van Buskirk, Mark
    Van Hazel, Guy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [33] Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)
    Yamazaki, K.
    Nagase, M.
    Tamagawa, H.
    Ueda, S.
    Tamura, T.
    Murata, K.
    Nakajima, T. Eguchi
    Baba, E.
    Tsuda, M.
    Moriwaki, T.
    Esaki, T.
    Tsuji, Y.
    Muro, K.
    Taira, K.
    Denda, T.
    Funai, S.
    Shinozaki, K.
    Yamashita, H.
    Sugimoto, N.
    Okuno, T.
    Nishina, T.
    Umeki, M.
    Kurimoto, T.
    Takayama, T.
    Tsuji, A.
    Yoshida, M.
    Hosokawa, A.
    Shibata, Y.
    Suyama, K.
    Okabe, M.
    Suzuki, K.
    Seki, N.
    Kawakami, K.
    Sato, M.
    Fujikawa, K.
    Hirashima, T.
    Shimura, T.
    Taku, K.
    Otsuji, T.
    Tamura, F.
    Shinozaki, E.
    Nakashima, K.
    Hara, H.
    Tsushima, T.
    Ando, M.
    Morita, S.
    Boku, N.
    Hyodo, I.
    ANNALS OF ONCOLOGY, 2016, 27 (08) : 1539 - 1546
  • [34] Cost-effectiveness analysis of FOLFOXIRI/FOLFOXIRI and mFOLFOX6/FOLFIRI treatment in first-line and second-line chemotherapy for metastatic colorectal cancer
    Li, Xianglian
    Bao, Jianan
    Ma, Jingjing
    BMJ OPEN, 2025, 15 (03):
  • [35] Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)
    Schmoll, Hans-Joachim
    Cunningham, David
    Sobrero, Alberto
    Karapetis, Christos S.
    Rougier, Philippe
    Koski, Sheryl L.
    Kocakova, Ilona
    Bondarenko, Igor
    Bodoky, Gyoergy
    Mainwaring, Paul
    Salazar, Ramon
    Barker, Peter
    Mookerjee, Bijoyesh
    Robertson, Jane
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (29) : 3588 - 3595
  • [36] PARADIGM study: A multicenter, randomized, phase III study of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer.
    Yoshino, Takayuki
    Uetake, Hiroyuki
    Tsuchihara, Katsuya
    Shitara, Kohei
    Yamazaki, Kentaro
    Oki, Eiji
    Sato, Takeo
    Naitoh, Takeshi
    Komatsu, Yoshito
    Kato, Takeshi
    Iwasaki, Kouji
    Soeda, Junpei
    Hihara, Masamitsu
    Yamanaka, Takeharu
    Ochiai, Atsushi
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [37] Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC) - an interim analysis of the CEBIFOX trial
    Hoehler, T.
    Decker, T.
    Schimanski, C.
    Schmitz, S.
    Kanzler, S.
    Rauh, J.
    Vehling-Kaiser, U.
    Bernhard, H.
    Hoffmann, T.
    Niederle, N.
    von Verschuer, U.
    von Wichert, G.
    Wagner, T.
    Klein, M.
    ONKOLOGIE, 2013, 36 : 105 - 105
  • [38] Tumor response outcomes in first-line treatment of wild-type (WT) RAS metastatic colorectal carcinoma (mCRC) following modified FOLFOX6 (mFOLFOX6) + either panitumumab (pmab) or bevacizumab (bev).
    Rivera, Fernando
    Karthaus, Meinolf
    Hecht, J. Randolph
    Fasola, Gianpiero
    Canon, Jean-Luc
    Koukakis, Reija
    Terwey, Jan-Henrik
    Schwartzberg, Lee Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [39] Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma
    Fernando Rivera
    Meinolf Karthaus
    J. Randolph Hecht
    Isabel Sevilla
    Frédéric Forget
    Gianpiero Fasola
    Jean-Luc Canon
    Xuesong Guan
    Gaston Demonty
    Lee S. Schwartzberg
    International Journal of Colorectal Disease, 2017, 32 : 1179 - 1190
  • [40] A randomized phase II study of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab for previously untreated, liver-limited metastatic colorectal cancer that is unsuitable for resection (ATOM trial).
    Uetake, Hiroyuki
    Emi, Yasunori
    Yamanaka, Takeharu
    Muro, Kei
    Oki, Eiji
    Takahashi, Takao
    Nagasaka, Takeshi
    Hatano, Etsuro
    Ojima, Hitoshi
    Manaka, Dai
    Kusumoto, Tetsuya
    Katayose, Yu
    Fujiwara, Toshiyoshi
    Yoshida, Kazuhiro
    Unno, Michiaki
    Hyodo, Ichinosuke
    Tomita, Naohiro
    Sugihara, Kenichi
    Maehara, Yoshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
12345